« Back
Home /
Lifitegrast

Lifitegrast

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	50 mg
Quantity options	100 mg 10 mM/1mL 10 mg 200mg 50 mg 5mg
Item no.	HY-19344-50mg
Targets	Integrin
CASRN	1025967-78-5
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	615.48
Clinical_Information	Launched
Manufacturers Research_Area	Inflammation/Immunology
Solubility	DMSO : ≥ 29 mg/mL
Manufacturers Target	Integrin
Isoform	αLβ2
Manufacturers Pathway	Cytoskeleton
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19344-50mg-safety-datasheet.pdf